Clinical Trials Sponsored by TORL Biotherapeutics, LLC

Total 22 results

TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Hepatocellular Carcinoma | Advanced Solid Tumor

United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Colorectal Cancer | Advanced Solid Tumor

United States, Canada
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Gastric Cancer | Advanced Solid Tumor | Pancreas Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer (TRIO049)

Ovarian Cancer | NSCLC | Advanced Solid Tumor | Endometrial Cancer

United States
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Gastric Cancer | Advanced Solid Tumor | Pancreas Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Dermelix Biotherapeutics, LLC.

Withdrawn

A Cross-Sectional Natural History Study to Evaluate Sweat Volume and Other Phenotypic and Genetic Characteristics in Patients Affected by XLHED

XLHED

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Terminated

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Ulcerative Colitis

United States
Aeglea Biotherapeutics
Merck Sharp & Dohme LLC

Completed

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Small-cell Lung Cancer

United States, Puerto Rico
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

Healthy Participants

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Healthy Participants

United States
Immorna Biotherapeutics, Inc.
ICON plc

Recruiting

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine

COVID-19 | Infectious Disease

United States
Immorna Biotherapeutics, Inc.
ICON plc

Active, not recruiting

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Infectious Disease | Shingles | Herpes Zoster (HZ)

United States
Asher Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

SARS-CoV 2

United States
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

SARS-CoV-2 Infection, COVID-19

United States
University of Rome Tor Vergata
Merck Sharp & Dohme LLC

Completed

Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome

Metabolic Syndrome

Italy

Clinical Trials Sponsored by TORL Biotherapeutics, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations